Meeting
2019 ASCO Annual Meeting
Randomized phase Ⅱ trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage Ⅲ non-squamous non-small-cell lung cancer: NJLCG1001.
Authors
Kana Watanabe
Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan
Kana Watanabe , Yukihiro Toi , Atsushi Nakamura , Tatsuro Fukuhara , Ryosuke Chiba , Masachika Akiyama , Jun Sakakibara-Konishi , Hisashi Tanaka , Naruo Yoshimura , Eisaku Miyauchi , Taku Nakagawa , Ryotaro Igusa , Hiroyuki Minemura , Yoshiaki Mori , Keisuke Fujimoto , Haruo Matsushita , Fumiaki Takahashi , Akira Inoue , Shunichi Sugawara , Makoto Maemondo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8527)
DOI
10.1200/JCO.2019.37.15_suppl.8527
Abstract #
8527
Poster Bd #
283
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.
First Author: Martin Reck
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2017 ASCO Annual Meeting
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (TORG1018).
First Author: Kaoru Kubota